Healthy men test two fabry drugs in Head-to-Head comparison
NCT ID NCT05343715
First seen Nov 01, 2025 · Last updated May 04, 2026 · Updated 19 times
Summary
This study tested two versions of the drug agalsidase beta (one from Biosidus, one from Sanofi) in 24 healthy men. Participants received a single dose by IV, and researchers measured how much drug got into the blood and how active it was. The goal was to see if the two versions work similarly, which could help provide more treatment options for people with Fabry disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for FABRY DISEASE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Sanatorio Nuestra Señora del Pilar
Ciudadela, Buenos Aires, 1702, Argentina
Conditions
Explore the condition pages connected to this study.